In non-small cell lung cancer, Douillard et al. showed 94% concordance between ctDNA and tumor EGFR mutation status, allowing for diagnosis and targeted treatment of EGFR mutations in patients with insufficient tissue quantity [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.